CpG oligodeoxynucleotides as TLR9 agonists

Therapeutic application in allergy and asthma

Gaurav K. Gupta, Devendra K. Agrawal

Research output: Contribution to journalReview article

57 Citations (Scopus)

Abstract

Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (Th)-2 cell-type responses. CpG ODNs can induce Th1 and T-regulatory (Treg) cell-type cytokines that can suppress the Th2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.

Original languageEnglish
Pages (from-to)225-235
Number of pages11
JournalBioDrugs
Volume24
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Oligodeoxyribonucleotides
Cytosine
Guanine
Hypersensitivity
Asthma
Phosphates
Therapeutics
Toll-Like Receptor 9
Bacterial DNA
Th2 Cells
Regulatory T-Lymphocytes
Immunotherapy
Communicable Diseases
Clinical Trials
Cytokines
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology
  • Medicine(all)

Cite this

CpG oligodeoxynucleotides as TLR9 agonists : Therapeutic application in allergy and asthma. / Gupta, Gaurav K.; Agrawal, Devendra K.

In: BioDrugs, Vol. 24, No. 4, 2010, p. 225-235.

Research output: Contribution to journalReview article

@article{7386fe40690a4da5a7268acc205fc1cd,
title = "CpG oligodeoxynucleotides as TLR9 agonists: Therapeutic application in allergy and asthma",
abstract = "Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (Th)-2 cell-type responses. CpG ODNs can induce Th1 and T-regulatory (Treg) cell-type cytokines that can suppress the Th2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.",
author = "Gupta, {Gaurav K.} and Agrawal, {Devendra K.}",
year = "2010",
doi = "10.2165/11536140-000000000-00000",
language = "English",
volume = "24",
pages = "225--235",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - CpG oligodeoxynucleotides as TLR9 agonists

T2 - Therapeutic application in allergy and asthma

AU - Gupta, Gaurav K.

AU - Agrawal, Devendra K.

PY - 2010

Y1 - 2010

N2 - Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (Th)-2 cell-type responses. CpG ODNs can induce Th1 and T-regulatory (Treg) cell-type cytokines that can suppress the Th2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.

AB - Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (Th)-2 cell-type responses. CpG ODNs can induce Th1 and T-regulatory (Treg) cell-type cytokines that can suppress the Th2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.

UR - http://www.scopus.com/inward/record.url?scp=77954589298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954589298&partnerID=8YFLogxK

U2 - 10.2165/11536140-000000000-00000

DO - 10.2165/11536140-000000000-00000

M3 - Review article

VL - 24

SP - 225

EP - 235

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 4

ER -